What is Integrity Laboratories?
Integrity Laboratories operates at the intersection of biotechnology and clinical diagnostics, positioning itself as a critical player in the field of antimicrobial stewardship. By leveraging advanced molecular diagnostics platforms such as the intercept PCR system and the RespiPlex AIO test, the company provides healthcare providers with the rapid, precise data necessary for targeted therapeutic interventions. This focus on actionable analytics not only enhances patient care but also aligns with the broader industry shift toward value-based care models. Through strategic partnerships with healthcare systems and insurance networks, Integrity Laboratories effectively bridges the gap between complex laboratory science and practical clinical application, ultimately driving down costs while improving diagnostic accuracy.
How much funding has Integrity Laboratories raised?
Integrity Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Integrity Laboratories
PPP
Public-Private Partnership
What's next for Integrity Laboratories?
Following this late-stage financing, Integrity Laboratories is well-positioned to scale its diagnostic infrastructure and expand its footprint within the competitive biotechnology landscape. The infusion of capital will likely be directed toward accelerating the deployment of its molecular diagnostic platforms and enhancing its data analytics capabilities. As the firm navigates this growth phase, the focus will remain on strengthening its integration with existing healthcare networks and refining its diagnostic portfolio to address emerging infectious disease challenges. By maintaining its commitment to precision medicine, the company is poised to influence the future of antimicrobial stewardship and solidify its status as a leader in the diagnostic sector.
See full Integrity Laboratories company page
